The head & neck cancers condition center is a comprehensive resource for clinical news and expert insights on head & neck cancers. Read more at OncLive.
July 16th 2025
In patients with HPV16-positive HNSCC, CUE-101 plus pembrolizumab generated 2 complete responses and a 12-month overall survival rate of 88%.
July 10th 2025
The European Commission has approved tislelizumab plus gemcitabine/cisplatin for adults with recurrent or metastatic nasopharyngeal carcinoma.
July 5th 2025
The FDA grants approval to sunvozertinib in NSCLC and linvoseltamab in myeloma and removes REMS requirements for approved CAR T-cell therapies.
July 1st 2025
Here is your guide to all therapeutic options that were cleared by the FDA in June 2025 spanning tumor types.
Ravindra Uppaluri, MD, PhD, discusses the FDA approval of pembrolizumab in the neoadjuvant and adjuvant setting for resectable, locally advanced HNSCC.
Experts in the fields of lung, head and neck, HER2+ breast, and hematologic cancers discuss notable updates for fellows from the 2025 AACR Annual Meeting.
June 30th 2025
OncLive® showcases 13 cancer care pioneers, who have won the 2025 Giants of Cancer Care award.
June 14th 2025
The FDA has approved new options in head and neck cancer, lung cancer, and bladder cancer—and more from OncLive this week.
June 12th 2025
Douglas R. Adkins, MD, discusses the FDA approval of pembrolizumab for neoadjuvant and adjuvant treatment in resectable, locally advanced head and neck squamous cell carcinoma.
The FDA has approved perioperative pembrolizumab adjuvant radiotherapy in resectable locally advanced HNSCC.
June 1st 2025
Patients with locally advanced, high-risk head and neck cancer showed significantly improved DFS with adjuvant nivolumab plus cisplatin and radiotherapy.
May 27th 2025
The EMA’s CHMP recommended the EU approval of first-line tislelizumab plus chemotherapy for adults with recurrent or metastatic nasopharyngeal carcinoma.
May 15th 2025
Aditya Shreenivas, MD, MS, discusses the FDA approval of penpulimab for recurrent/metastatic non-keratinizing NPC.
May 7th 2025
OncLive announces the inductees of the 13th annual Giants of Cancer Care recognition program.
May 5th 2025
Treatment with eftilagimod alpha plus pembrolizumab produced a median OS of 17.6 months in the first line for patients with PD-L1–negative HNSCC.
April 29th 2025
Glenn J. Hanna, MD, discusses the efficacy of elraglusib plus chemotherapy with or without immunotherapy in patients with advanced salivary gland cancer.
April 27th 2025
Perioperative pembrolizumab with postoperative radiation with or without cisplatin showed durable EFS in resectable, locally advanced HNSCC.
April 24th 2025
The FDA has approved penpulimab for select patients with non-keratinizing nasopharyngeal carcinoma.
Zafar Sayed, MD, explains advances in surgical head and neck cancer approaches, including the use of transoral robotic surgery.
April 23rd 2025
Akina Tamaki, MD, highlights treatment considerations, the therapeutic arsenal, and surgical advancements in head and neck cancer.